Literature DB >> 7507316

Immunosuppressants: tools to investigate the physiological role of cytokines.

V F Quesniaux1.   

Abstract

The cyclic peptide Cyclosporine A (CsA) is best known as the immunosuppressive drug which has revolutionized organ transplantation. It selectively suppresses T cell activation by blocking the transcription of cytokine genes such as IL-2 at the level of transcription factor modulation. The structurally unrelated immunosuppressant FK 506 acts on the same pathway and blocks cytokine gene expression. In contrast, rapamycin, a structural analogue of FK 506, interferes with the immune response at a different level, by blocking the response induced by cytokines such as IL-2. Although these drugs have been most studied for their immunosuppressive activities, it is clear that their effects on cytokine pathways extend far beyond the sole IL-2-mediated responses involved in the immune response. For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6. Here, we recap what is known about the effects of CsA, FK 506 and rapamycin on hematopoiesis in vitro and in vivo and extrapolate on what these drugs can teach us about the physiological role of cytokines for hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507316     DOI: 10.1002/bies.950151106

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  10 in total

Review 1.  Immune mechanisms in uveitis.

Authors:  R R Caspi
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Quantitative assessment of complex formation of nuclear-receptor accessory proteins.

Authors:  K Graumann; A Jungbauer
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  Elevated serum cyclophilin levels in patients with severe sepsis.

Authors:  I Tegeder; A Schumacher; S John; H Geiger; G Geisslinger; H Bang; K Brune
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

Review 4.  Transcription factors as drug targets: opportunities for therapeutic selectivity.

Authors:  T R Butt; S K Karathanasis
Journal:  Gene Expr       Date:  1995

5.  Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia.

Authors:  Y Novik; L Oleksowicz; P H Wiernik
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

6.  Inhibition of mTOR Alleviates Early Brain Injury After Subarachnoid Hemorrhage Via Relieving Excessive Mitochondrial Fission.

Authors:  Yuchen Li; Pei Wu; Jiaxing Dai; Tongyu Zhang; Ji Bihl; Chunlei Wang; Yao Liu; Huaizhang Shi
Journal:  Cell Mol Neurobiol       Date:  2019-11-15       Impact factor: 5.046

7.  In situ expression of cytokines in human heart allografts.

Authors:  E Van Hoffen; D Van Wichen; I Stuij; N De Jonge; C Klöpping; J Lahpor; J Van Den Tweel; F Gmelig-Meyling; R De Weger
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

8.  Relative quantification of mRNA levels in Jurkat T cells with RT-real time-PCR (RT-rt-PCR): new possibilities for the screening of anti-inflammatory and cytotoxic compounds.

Authors:  Jürg Gertsch; Martin Güttinger; Otto Sticher; Jörg Heilmann
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

9.  Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits.

Authors:  V C Dias; K L Madsen; K E Mulder; M Keelan; R W Yatscoff; A B Thomson
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

10.  Deficient IFN-gamma expression in umbilical cord blood (UCB) T cells can be rescued by IFN-gamma-mediated increase in NFATc2 expression.

Authors:  Suzanne Kadereit; Gwendolyn R Junge; Thomas Kleen; Margaret M Kozik; Beth A Kaminski; Kathleen Daum-Woods; Pingfu Fu; Magdalena Tary-Lehmann; Mary J Laughlin
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.